🔗 Share this article

Elected officials have issued warnings that the United Kingdom's negotiated accords with the US administration are "fundamentally unstable." This follows revelations that a much-touted deal on medicines, which pledges zero tariffs in exchange for the NHS increasing its costs, lacks any detailed agreement beyond limited headline terms published in government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, hailed as a "significant" achievement, remains an "statement of intent" without detailed provisions. Observers point out that the public statements from the UK and US governments present the deal in sharply different terms. The British version focuses on securing "zero per cent tariffs" as a singular success, while the American announcement concentrates on the commitment for the NHS to pay significantly more for new medications.

"The danger exists that the UK government has agreed to terms to raise drug prices in return for nothing more than a verbal promise from President Trump," commented David Henig, a trade policy analyst. "We know he has form for not honouring his word."

Broader Instability and a Paused Tech Deal

Worries have been amplified by Washington's recent decision to suspend the £31bn "tech prosperity deal", which was previously heralded as "a transformative pact" in the bilateral relationship. The US claimed a failure to advance from the UK on addressing wider trade issues as the reason for the pause.

Furthermore, concessions promised for British farmers as part of an initial accord have still not been formally approved by the US, despite a fast-approaching January deadline. "Our understanding is that the US has failed to approve the agreed beef export quotas," said Tom Bradshaw of the National Farmers' Union.

Private Ministerial Concerns

Behind the scenes, ministers have expressed concerns that the government's deals with Washington are lacking substance. One minister reportedly said the series of agreements as "resting on shaky ground," while another described the situation as the "new normal" in the transatlantic relationship, marked by "greater risk and fluctuation."

Layla Moran, chair of the health select committee, remarked: "The only thing more surprising than the US approach is the UK government's credulous faith that his administration is a reliable partner. The NHS is not a bargaining chip."

Official Reassurances and Concrete Outcomes

Government figures have attempted to minimize the possibility of the US withdrawing from the pharmaceuticals deal. One source noted the US pharmaceutical industry itself had been lobbying for the agreement, seeking certainty on imports and pricing, making it of tangible value than the paused tech deal.

Officials acknowledge that volatility is a feature of dealing with the Trump administration. However, they argue that the UK has obtained tangible results for businesses, such as reduced duties on automobiles compared to other nations. "Securing 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

Nevertheless, delays have arisen in enacting the broader trade deal. Promised access for British beef have failed to be approved, and the assurance to "remove tariffs on British steel and aluminium" has not been fulfilled, with tariffs staying at 25%.

Moving forward, the two sides have scheduled to restart talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.